Deprecated: bp_before_xprofile_cover_image_settings_parse_args is deprecated since version 6.0.0! Use bp_before_members_cover_image_settings_parse_args instead. in /home/top4art.com/public_html/wp-includes/functions.php on line 5094
  • Nicholson Boll posted an update 1 week ago

    The report of symptom experience and its change revealed a unique pattern of symptom perception. The three other themes illustrated the impact of multiple concurrent symptoms on daily living, namely “decreased physical functioning,” “changes in social functioning” and “diet and fluid restrictions.” CONCLUSIONS Patients perceived dynamic and complex symptom experiences. This perception appears to be modulated by a number of factors. In addition, these experiences had negative and positive effects on patients’ daily living. RELEVANCE TO CLINICAL PRACTICE Patients perceived unique impact of symptoms on daily living. Therefore, a nurse-led person-centred approach of care is warranted. In addition to routine symptom assessment, nurses need to capture the specific impact of symptoms on day-to-day life. Based on this assessment, symptom management interventions (e.g. health education, referral) can be tailor-made and prioritised. © 2020 John Wiley & Sons Ltd.BACKGROUND The treatment of active antibody-mediated rejection (ABMR) is still a matter of debate, the place of rituximab remaining controversial. The French multicenter double-blind RITUX-ERAH study included 38 patients with ABMR in the first year of renal transplantation. All patients received plasma exchanges, intravenous immunoglobulins, corticosteroids and were randomly assigned rituximab or placebo infusion at day 5. Additional rituximab infusions were allowed. In the intention-to-treat analysis, 12-month graft survival and renal function were not different between the rituximab and placebo groups. Long-term data are needed to conclude. METHODS Evaluation of the 7-year outcomes of the RITUX-ERAH study patients according to the rituximab or placebo treatment received. RESULTS Eleven patients received placebo and 27 at least one infusion of rituximab. Seven years after ABMR, death-censored kidney allograft survival and renal function were not different between the groups. The evolution of anti-HLA sensitization was similar. There was no statistically significant difference in the incidence of infectious or neoplastic complications, but to be noted, 7 cancers developed in 6 patients treated with rituximab (mean period of 44 months post ABMR). CONCLUSION In this cohort, there was no benefit 7 years after ABMR of rituximab in addition with plasma exchanges, intravenous immunoglobulins and steroids. This article is protected by copyright. All rights reserved.AIMS AND OBJECTIVES To describe individuals with type 2 diabetes mellitus sensemaking of blood glucose data and other influences impacting self-management behavior. BACKGROUND Type 2 diabetes mellitus prevalence is increasing globally. Adherence to effective diabetes self-management regimens is an ongoing health care challenge. Examining individuals’ sensemaking processes can advance staff knowledge of and improve diabetes self-management behavior. DESIGN A qualitative exploratory design examining how individuals make sense of blood glucose data and symptoms, and the influence on self-management decisions. METHODS Sixteen one-on-one interviews with adults diagnosed with type 2 diabetes mellitus using a semi-structured interview guide were conducted March to May 2018. An inductive-deductive thematic analysis of data using the Sensemaking Framework for Chronic Disease Self-Management was utilized. The consolidated criteria for reporting qualitative research (COREQ) checklist was used in completing this paper. R PRACTICE Nurses must assess sensemaking processes in self-management decisions. Periodic “refresher” diabetes education may be needed for individuals with type 2 diabetes mellitus. This article is protected by copyright. All rights reserved.Emerging fungal diseases have become challenges for wildlife health and conservation. North American hibernating bat species are threatened by the psychrophilic fungus Pseudogymnoascus destructans (Pd) causing the disease called white-nose syndrome (WNS) with unprecedented mortality rates. The fungus is widespread in North America and Europe, however, disease is not manifested in European bats. Differences in epidemiology and pathology indicate an evolution of resistance or tolerance mechanisms towards Pd in European bats. We compared the proteomic profile of blood plasma in healthy and Pd-colonized European Myotis myotis and North American Myotis lucifugus in order to identify patho-physiological changes associated with Pd colonization, which might also explain the differences in bat survival. Expression analyses of plasma proteins revealed differences in healthy and Pd-colonized M. lucifugus, but not in M. myotis. We identified differentially expressed proteins for acute phase response, constitutive and adaptive immunity, oxidative stress defense, metabolism and structural proteins of exosomes and desmosomes, suggesting a systemic response against Pd in North American M. lucifugus but not European M. myotis. The differences in plasma proteomic profiles between European and North American bat species colonized by Pd suggest European bats have evolved tolerance mechanisms towards Pd infection. This article is protected by copyright. All rights reserved.The human pathogen Pseudomonas aeruginosa harbors three paralogous zinc proteases annotated as AmpD, AmpDh2, and AmpDh3, which turn over the cell wall and cell wall-derived muropeptides. AmpD is cytoplasmic and plays a role in the recycling of cell wall muropeptides, with a link to antibiotic resistance. AmpDh2 is a periplasmic soluble enzyme with the former anchored to the inner leaflet of the outer membrane. We document, herein, that the type VI secretion system locus II (H2-T6SS) of P. All-trans Retinoic Acid aeruginosa delivers AmpDh3 (but not AmpD or AmpDh2) to the periplasm of a prey bacterium upon contact. AmpDh3 hydrolyzes the cell wall peptidoglycan of the prey bacterium, which leads to its killing, thereby providing a growth advantage for P. aeruginosa in bacterial competition. We also document that the periplasmic protein PA0808, heretofore of unknown function, affords self-protection from lysis by AmpDh3. Cognates of the AmpDh3-PA0808 pair are widely distributed across Gram-negative bacteria. Taken together, these findings underscore the importance of their function as an evolutionary advantage and that of the H2-T6SS as the means for the manifestation of the effect.

Facebook Pagelike Widget

Who’s Online

Profile picture of Hamann Bille
Profile picture of Munk Herman
Profile picture of Lauridsen McCollum
Profile picture of Storm Krag
Profile picture of Axelsen Appel
Profile picture of Oh Howard
Profile picture of Watts Bentley
Profile picture of Mathiassen Wong
Profile picture of Clapp Hays
Profile picture of Rode Reilly
Profile picture of Collins Hancock
Profile picture of Abbott Terkelsen
Profile picture of Pridgen Kruse